Member States must commit to invest in TB vaccine R&D
A one-pager, developed by TB Vax ARM, provides relevant background information on the critical need for Member States to substantially increase adequate, predictable, and sustainable financing for TB vaccine research.
The TB Vaccine Advocacy Roadmap (TB Vax ARM) developed a one-pager on why Member States must commit to invest in TB vaccine research and development (R&D). The one-pager provides relevant background information on the critical need for Member States to substantially increase adequate, predictable, and sustainable financing for TB vaccine research to reach the annual $1.25 billion funding target and develop and roll-out new TB vaccines within the next five years, no later than 2028.
Download the document here.
